English   español  
Por favor, use este identificador para citar o enlazar a este item: http://hdl.handle.net/10261/154777
COMPARTIR / IMPACTO:
Estadísticas
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:
Campo DC Valor Lengua/Idioma
dc.contributor.authorMorales-García, José A.es_ES
dc.contributor.authorSalado, Irene G.es_ES
dc.contributor.authorSanz-SanCristóbal, Marinaes_ES
dc.contributor.authorGil, Carmenes_ES
dc.contributor.authorPérez Castillo, Anaes_ES
dc.contributor.authorMartínez, Anaes_ES
dc.contributor.authorPérez, Daniel I.es_ES
dc.date.accessioned2017-09-05T12:18:57Z-
dc.date.available2017-09-05T12:18:57Z-
dc.date.issued2017-08-30-
dc.identifier.citationACS Omega 2 (8), pp 5215–5220 (2017)es_ES
dc.identifier.urihttp://hdl.handle.net/10261/154777-
dc.description6 p.-3 fig.-2 tab.es_ES
dc.description.abstractParkinson’s disease (PD), an age-related neurodegenerative disorder that results from a progressive loss of dopaminergic neurons has an enormous economical and human cost. Unfortunately, only symptomatic treatment such as dopamine replacement therapy is available. Therefore, drugs with new mechanisms of action able to protect against neuronal cell death are an urgent need. We here report the in vivo efficacy on dopaminergic neuronal protection in a PD mouse model and the lack of toxicity in zebrafish and Ames test of benzothiazole-based casein kinase-1δ (CK-1δ) nanomolar inhibitors. On the basis of these results, we propose protein kinase CK-1δ inhibitors as the possible disease-modifying drugs for PD, benzothiazole 4 being a promising drug candidate for further development as a new therapy of this neurodegenerative disease.es_ES
dc.description.sponsorshipThis work was supported by grants from MINECO (SAF2012-37979-C03-01 to A.M. and SAF2014-52940-R to A.P.-C.) and from MICINN (grant SAF2010-16365 to A.P.-C.). I.G.S. and D.I.P. acknowledge a pre- and postdoctoral fellowship from MICINN (FPI program) and CSIC (JAE program), respectively. CIBERNED is funded by the Instituto de Salud Carlos III. J.A.M.-G. is a fellow from CIBERNED.es_ES
dc.language.isoenges_ES
dc.publisherAmerican Chemical Societyes_ES
dc.relationMINECO/ICTI2013-2016/SAF2014-52940-R-
dc.relation.isversionofPublisher's versiones_ES
dc.rightsopenAccessen_EN
dc.subjectDrug discovery and Drug delivery systemses_ES
dc.subjectHeterocyclic compoundses_ES
dc.subjectStructure-activity relationshipes_ES
dc.titleBiological and pharmacological characterization of benzothiazole-based CK-1δ inhibitors in models of Parkinson’s diseasees_ES
dc.typeArtículoes_ES
dc.identifier.doi10.1021/acsomega.7b00869-
dc.description.peerreviewedPeer reviewedes_ES
dc.relation.publisherversionhttp://dx.doi.org/10.1021/acsomega.7b00869es_ES
dc.identifier.e-issn2470-1343-
dc.embargo.terms2018-08-30es_ES
dc.contributor.funderMinisterio de Economía y Competitividad (España)es_ES
dc.contributor.funderMinisterio de Economía, Industria y Competitividad (España)es_ES
dc.contributor.funderConsejo Superior de Investigaciones Científicas (España)es_ES
dc.contributor.funderInstituto de Salud Carlos IIIes_ES
dc.relation.csices_ES
oprm.item.hasRevisionno ko 0 false*
dc.identifier.funderhttp://dx.doi.org/10.13039/501100004587es_ES
dc.identifier.funderhttp://dx.doi.org/10.13039/501100003329es_ES
dc.identifier.funderhttp://dx.doi.org/10.13039/501100003339es_ES
Aparece en las colecciones: (CIB) Artículos
Ficheros en este ítem:
Fichero Descripción Tamaño Formato  
acsomega.7b00869.pdfArtículo principal5,3 MBAdobe PDFVista previa
Visualizar/Abrir
Show simple item record
 

Artículos relacionados:


NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.